Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]TARP-v8 is a novel positron emission tomography (PET) radiotracer developed by The First Affiliated Hospital of Jinan University for the visualization and quantification of transmembrane AMPA receptor regulatory protein gamma-8 (TARP-γ8) in the human brain. TARP-γ8 is a specific auxiliary subunit that modulates the trafficking, surface expression, and biophysical properties of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, with high expression levels found in the hippocampus. The tracer is currently being utilized in clinical research (e.g., ChiCTR2600123144) to investigate glutamatergic system abnormalities in patients with major depressive disorder (MDD). By mapping TARP-γ8 distribution, researchers aim to identify biomarkers for MDD and understand the relationship between AMPA receptor regulation and clinical depressive symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]TARP-v8.